Absci Corporation · NASDAQ:ABSI

Absci — Jefferies Healthcare Conference (2026)

23 slides from Absci's conference presentation, 2026

Slide 2: Disclaimers
DISCLOSURES Disclaimers 1 2 FORWARD-LOOKING STATEMENTS MARKET AND STATISTICAL Statements contained in this press release regarding matters that are not historical INFORMATION facts are “forward-looking statements” within the meaning of the Private Securities This presentation also contains estimates
Slide 3: From Code to Clinic
ABSCI | INTRO 1. AI NATIVE PLATFORM From o Interdisciplinary Team with 10+ approved drugs and AI expertise o Integrated Lab-in-the-Loop leveraging 77k ft² automated wet-lab Code to o Leading AI platform for de novo design and AI optimization of antibody-based therapeutics 2. DIFFERENTIATED PIPELINE
Slide 4: Industrializing Drug Discovery: From Code to Clinic
FROM CODE TO CLINIC Industrializing Drug Discovery $10-15mil (Absci) DATA TO 1 INVESTMENT TRAIN $50-100mil (Large Pharma) ABS-201 FOR ANDROGENETI C ALOPECI A CAPITAL Category re-defining opportunity for AGA in Ph1/2a trials 24 Months (Absci) 6-week Lab in the loop cycles 2 ABS-201 FOR ENDOMETRI OSI
Slide 5: We use AI to create novel & differentiated therapeutics
AI PLATFORM We use AI to create novel & differentiated therapeutics EPITOPE-SPECIFIC DESIGN + EPITOPE INTERFACE OPTIMIZATION ENHANCED POTENCY AND MOA ABILITY TO ADDRESS DIFFICULT TARGET CLASSES, E.G. GPCRS ENABLING FEATURES: MULTI-VALENCY, pH-DEPENDENT BINDING POTENTIAL TO CREATE MEANINGFUL IP: 100S
Slide 6: Origin-1: an AI platform for de novo antibody design against zero-prior epitopes
AI PLATFORM Origin-1: an AI platform for de novo antibody design against zero- prior epitopes Zero-Prior Epitope Targeting High Structural Fidelity Functional Antagonist Designed full-length mAbs against Cryo-EM confirmed designs at 3.0–3.1 Å AI-guided affinity maturation yielded epitopes with no kn
Slide 7: Advancing and expanding our pipeline of novel & differentiated assets designed using AI
PIPELINE Advancing and expanding our pipeline of novel & differentiated assets designed using AI Lead DC IND* THERAPEUTIC TARGET ID LEAD ID CANDIDATE ID IND-ENABLING PHASE 1 PHASE 2 AREA ABS- 201 Androgenetic Alopecia (PRLR) Ph1 / 2a PROLACTIN FOCUSED Endometriosis (PRLR) Ph1 PIPELINE ABS- 202 Immun
Slide 8: ABS-201 has the potential to unlock a wholly new category of therapy in hair re-growth
ABS-201 ABS-201 has the potential to unlock a wholly new category of therapy in hair “re-growth” 1. Significant clinical and commercial unmet need in androgenetic alopecia 2. Strong scientific rationale, with validated target, de-risked Mode of Action, and pharmacology 3. Straightforward development
Slide 9: PRLR inhibition for androgenetic alopecia is an innovative alternative
ABS-201 | AGA PRLR inhibition for androgenetic alopecia is an innovative alternative to current treatment options ABS-201 HAS THE PROPOSED DIRECT IMPACT OF ABS-201 ON HAIR CYCLE STAGES POTENTIAL TO: o Shift the balance in hair cycle stage Catagen towards anagen phase1,2 with: ↑↑ Apoptosis & Regressi
Slide 10: ABS-201 shows superior efficacy vs 5% topical minoxidil in 21d hair regrowth model
ABS-201 AGA ABS-201 shows superior efficacy vs 5% topical minoxidil in 21d hair regrowth model Hair Growth Score ABS-201 vs minoxidil/untreated/isotype **p<0.05; ***p<0.0001 - 2way ANOVA Administration: mAbs i.p. biweekly; Minoxidil topical daily COPYRIGHT © 2026 ABSCI CORPORATION | ALL RIGHTS RESER
Slide 11: Primate model of androgenetic alopecia: hair regrowth with PRLR blockade
ABS 201 | AGA Top head view of Stumptailed Macaque’s showing Terminal hair count ”Thick phenotypic change over time Hairs” in prior bald areas ASSESSMENT AREA = R1 TREATMENT POST-TREATMENT 300 BASELI NE 12 WEEKS 28 WEEKS 6 MONTHS 2 YEARS 4 YEARS 250 # Thick Hairs 200 MALE 150 100 50 FEMALE 0 4 8 12
Slide 12: ABS-201 in human ex vivo culture study supports MOA in human scalp follicles
ABS-201 | AGA ABS-201 in human ex vivo culture study supports MOA in human scalp follicles Frontotemporal ABS-201 significantly prolongs anagen/inhibits catagen and Hairline Region stimulates hair matrix proliferation Scalp Punch Microscopic hair cycle staging 100 80 % of HFs in each hair 60 cycle s
Slide 13: ABS-201 promotes HF epithelial stem cells and prevents their exhaustion
ABS-201 | AGA ABS-201 promotes HF epithelial stem cells and prevents their exhaustion RAS7A8L908:I;<0 =>((?A:@ACA>ABC("> 4 S7A8L908:I;<0AA=>((? aS(bA=Ac@">AS7 R d!"#ABC'(AeALf - L o Blocking PRLR signaling stabilizes and expands the stem cell pool in male scalp HFs ex vivo K !"#ABC'( FG+I-KL !"#A FG
Slide 14: Additional ABS-201 ex vivo study found
ABS-201 | AGA Additional ABS-201 ex Stem Cell Protection & Maintenance vivo study found: (↑K15+ Stem Cells) o Prolonging anagen phase and blocking catagen, thereby inhibiting telogen effluvium ↑ FGF7 and IGF1 Expression o Protecting and promoting hair follicle stem cells and and restoring CD34+ prog
Slide 15: Phase 1/2a trial designed to provide readouts on safety, tolerability, and PoC in AGA
ABS-201 | AGA Phase 1/2a trial designed to Single Ascending Dose provide readouts on safety, Cohort 1 Cohort 2 Cohort 3 Cohort 4 tolerability, and PoC in AGA 150mg IV 450mg IV 900mg IV 1800mg IV n=8 n=8 n=8 n=8 o Initiated December 2025 Design Elements: o All planned SAD cohorts dosed o Double-Blind
Slide 16: ABS-201 TPP aims to offer a new treatment category in AGA
ABS-201 | AGA ABS-201 | AGA ABS-201 TPP aims to offer 80 a new treatment category 70 Transplant + oral/topical in AGA based on efficacy and convenience 60 Efficacy (terminal hairs/cm2) Increased TAM o Novel, targeted regenerative hair follicle 50 mechanism o Convenient, infrequent pulse therapy: 2-3
Slide 17: 80M Patient Funnel
ABS-201 | AGA Total AGA pts in the US 50M male, 30M female 80M Patient Funnel Income ≥$75K (US Census) Pts 17-69 yo ~39M >$25B ESTIMATED U.S. TAM Concerned / motivated about hair loss ~26M Strong interest in TPP ~22 – 24M >$40B POTENTIAL GLOBAL TAM Strongest interest in TPP with premium price-to-per
Slide 18: Development of ABS-201 in Endometriosis
ABS 201 | ENDOMETRIOSIS Development of ABS-201 in Endometriosis 1. Addresses Long-standing Unmet Medical Need and Poor standard of care Strong Biological And Clinical 2. Rationale: Including POC for PRLR mechanism in humans 3. Large, untapped market offers significant upside potential COPYRIGHT© 202
Slide 19: PRLR antagonism is a novel and differentiated MoA in Endometriosis
ABS-201 | ENDOMETRIOSIS PRLR antagonism is a novel and differentiated MoA in Endometriosis o Endometriotic lesions produce prolactin under estrogen/progesterone control. PRL and PRLR play a dual role in endometrial lesion development o Excess prolactin promotes lesion growth and pain response and se
Slide 20: PRLR antagonism reduces lesion formation and pain in endometriosis mouse model
ABS-201 | ENDOMETRIOSIS PRLR antagonism reduces lesion formation and pain in endometriosis mouse model Prolactin inhibition decreases endometrial lesion formation in % Distance travelled at Week 7 female mouse interna (compared to baseline) 5 * * * Disease Score 4 3 2 lgG1 – w/o transplant 1 * 0 lgG
Slide 21: ABS-201: a potentially differentiated profile targeting a large underserved market
ABS-201 | ENDOMETRIOSIS ABS-201: a potentially differentiated profile targeting a large underserved market opportunity NOVEL TR EATMENT OPTI ON FOR ~ 9 M PATI ENTS I N THE U . S . AL ONE WI TH ENDOMETR I OS I S o Novel Mechanism: Non–sex- o Best-in-class Potential: steroid (peptide) hormone Superior
Slide 22: Leading AI x Bio platform driving Phase readouts in the next 24 months
CATALYSTS Leading AI x Bio platform driving 2 Phase 2 readouts in the next 24 months ABS-201 in AGA ABS-201 in ENDO o Ph1/2a Study initiated Dec o Ph1/2a Study initiated Dec 2025 2025 o Safety, Tolerability, and PK o Phase 2 initiation expected in readout expected 1H 2026 Q4 2026 o Interim PoC Reado

Absci — Jefferies Healthcare Conference (2026) on 6ix

Absci — Jefferies Healthcare Conference (2026)

Slide 1: Generative AI Drug Creation

Slide 2: Disclaimers

Slide 3: From Code to Clinic

Slide 4: Industrializing Drug Discovery: From Code to Clinic

Slide 5: We use AI to create novel & differentiated therapeutics

Slide 6: Origin-1: an AI platform for de novo antibody design against zero-prior epitopes

Slide 7: Advancing and expanding our pipeline of novel & differentiated assets designed using AI

Slide 8: ABS-201 has the potential to unlock a wholly new category of therapy in hair re-growth

Slide 9: PRLR inhibition for androgenetic alopecia is an innovative alternative

Slide 10: ABS-201 shows superior efficacy vs 5% topical minoxidil in 21d hair regrowth model

Slide 11: Primate model of androgenetic alopecia: hair regrowth with PRLR blockade

Slide 12: ABS-201 in human ex vivo culture study supports MOA in human scalp follicles

Slide 13: ABS-201 promotes HF epithelial stem cells and prevents their exhaustion

Slide 14: Additional ABS-201 ex vivo study found

Slide 15: Phase 1/2a trial designed to provide readouts on safety, tolerability, and PoC in AGA

Slide 16: ABS-201 TPP aims to offer a new treatment category in AGA

Slide 17: 80M Patient Funnel

Slide 18: Development of ABS-201 in Endometriosis

Slide 19: PRLR antagonism is a novel and differentiated MoA in Endometriosis

Slide 20: PRLR antagonism reduces lesion formation and pain in endometriosis mouse model

Slide 21: ABS-201: a potentially differentiated profile targeting a large underserved market

Slide 22: Leading AI x Bio platform driving Phase readouts in the next 24 months

Slide 23: Generative AI Re(Generative) Biology